Independent Research set a €93.00 ($108.14) target price on Carl Zeiss Meditec (ETR:AFX) in a research report sent to investors on Thursday, Borsen Zeitung reports. The firm currently has a sell rating on the stock.

AFX has been the topic of a number of other research reports. Berenberg Bank set a €114.00 ($132.56) target price on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a research report on Thursday, January 23rd. HSBC set a €109.00 ($126.74) target price on shares of Carl Zeiss Meditec and gave the stock a neutral rating in a research report on Tuesday, December 10th. Nord/LB set a €132.00 ($153.49) target price on shares of Carl Zeiss Meditec and gave the stock a buy rating in a research report on Wednesday. Deutsche Bank set a €140.00 ($162.79) target price on shares of Carl Zeiss Meditec and gave the stock a buy rating in a research report on Tuesday. Finally, DZ Bank restated a neutral rating on shares of Carl Zeiss Meditec in a research report on Thursday. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Carl Zeiss Meditec has a consensus rating of Hold and a consensus target price of €111.14 ($129.24).

ETR AFX traded down €0.60 ($0.70) during mid-day trading on Thursday, reaching €108.90 ($126.63). 127,710 shares of the stock were exchanged, compared to its average volume of 94,405. Carl Zeiss Meditec has a 1-year low of €71.25 ($82.85) and a 1-year high of €122.10 ($141.98). The business’s fifty day simple moving average is €115.95 and its 200 day simple moving average is €106.71. The stock has a market capitalization of $9.74 billion and a PE ratio of 57.44. The company has a debt-to-equity ratio of 4.06, a quick ratio of 3.01 and a current ratio of 3.84.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.

Featured Story: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Carl Zeiss Meditec (ETR:AFX)

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.